Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes

Graeme Eisenhofer, McClellan M. Walther, Thanh Truc Huynh, Sheng Ting Li, Stefan R. Bornstein, Alexander Vortmeyer, Massimo Mannelli, David S. Goldstein, W. Marston Linehan, Jacques W.M. Lenders, Karel Pacak

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

This study examined the mechanisms linking different biochemical and clinical phenotypes of pheochromocytoma in multiple endocrine neoplasia type 2 (MEN 2) and von Hippel-Lindau (VHL) syndrome to underlying differences in the expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, and of phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts norepinephrine to epinephrine. Signs and symptoms of pheochromocytoma, plasma catecholamines and metanephrines, and tumor cell neurochemistry and expression of TH and PNMT were examined in 19 MEN 2 patients and 30 VHL patients with adrenal pheochromocytomas. MEN 2 patients were more symptomatic and had a higher incidence of hypertension (mainly paroxysmal) and higher plasma concentrations of metanephrines, but paradoxically lower total plasma concentrations of catecholamines, than VHL patients. MEN 2 patients all had elevated plasma concentrations of the epinephrine metabolite, metanephrine, whereas VHL patients showed specific increases in the norepinephrine metabolite, normetanephrine. The above differences in clinical presentation were largely explained by lower total tissue contents of catecholamines and expression of TH and negligible stores of epinephrine and expression of PNMT in pheochromocytomas from VHL than from MEN 2 patients. Thus, mutation-dependent differences in the expression of genes controlling catecholamine synthesis represent molecular mechanisms linking the underlying mutation to differences in clinical presentation of pheochromocytoma in patients with MEN 2 and the VHL syndrome.

Original languageEnglish (US)
Pages (from-to)1999-2008
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume86
Issue number5
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Multiple Endocrine Neoplasia Type 2a
von Hippel-Lindau Disease
Pheochromocytoma
Catecholamines
Metanephrine
Phenylethanolamine N-Methyltransferase
Phenotype
Epinephrine
Plasmas
Tyrosine 3-Monooxygenase
Metabolites
Norepinephrine
Normetanephrine
Enzymes
Tumors
Neurochemistry
Mutation
Genes
Cells
Tissue

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. / Eisenhofer, Graeme; Walther, McClellan M.; Huynh, Thanh Truc; Li, Sheng Ting; Bornstein, Stefan R.; Vortmeyer, Alexander; Mannelli, Massimo; Goldstein, David S.; Linehan, W. Marston; Lenders, Jacques W.M.; Pacak, Karel.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 86, No. 5, 01.01.2001, p. 1999-2008.

Research output: Contribution to journalArticle

Eisenhofer, G, Walther, MM, Huynh, TT, Li, ST, Bornstein, SR, Vortmeyer, A, Mannelli, M, Goldstein, DS, Linehan, WM, Lenders, JWM & Pacak, K 2001, 'Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes', Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 1999-2008. https://doi.org/10.1210/jcem.86.5.7496
Eisenhofer, Graeme ; Walther, McClellan M. ; Huynh, Thanh Truc ; Li, Sheng Ting ; Bornstein, Stefan R. ; Vortmeyer, Alexander ; Mannelli, Massimo ; Goldstein, David S. ; Linehan, W. Marston ; Lenders, Jacques W.M. ; Pacak, Karel. / Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. In: Journal of Clinical Endocrinology and Metabolism. 2001 ; Vol. 86, No. 5. pp. 1999-2008.
@article{b475ae02e9c24a279e07c63b0abfbc8b,
title = "Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes",
abstract = "This study examined the mechanisms linking different biochemical and clinical phenotypes of pheochromocytoma in multiple endocrine neoplasia type 2 (MEN 2) and von Hippel-Lindau (VHL) syndrome to underlying differences in the expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, and of phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts norepinephrine to epinephrine. Signs and symptoms of pheochromocytoma, plasma catecholamines and metanephrines, and tumor cell neurochemistry and expression of TH and PNMT were examined in 19 MEN 2 patients and 30 VHL patients with adrenal pheochromocytomas. MEN 2 patients were more symptomatic and had a higher incidence of hypertension (mainly paroxysmal) and higher plasma concentrations of metanephrines, but paradoxically lower total plasma concentrations of catecholamines, than VHL patients. MEN 2 patients all had elevated plasma concentrations of the epinephrine metabolite, metanephrine, whereas VHL patients showed specific increases in the norepinephrine metabolite, normetanephrine. The above differences in clinical presentation were largely explained by lower total tissue contents of catecholamines and expression of TH and negligible stores of epinephrine and expression of PNMT in pheochromocytomas from VHL than from MEN 2 patients. Thus, mutation-dependent differences in the expression of genes controlling catecholamine synthesis represent molecular mechanisms linking the underlying mutation to differences in clinical presentation of pheochromocytoma in patients with MEN 2 and the VHL syndrome.",
author = "Graeme Eisenhofer and Walther, {McClellan M.} and Huynh, {Thanh Truc} and Li, {Sheng Ting} and Bornstein, {Stefan R.} and Alexander Vortmeyer and Massimo Mannelli and Goldstein, {David S.} and Linehan, {W. Marston} and Lenders, {Jacques W.M.} and Karel Pacak",
year = "2001",
month = "1",
day = "1",
doi = "10.1210/jcem.86.5.7496",
language = "English (US)",
volume = "86",
pages = "1999--2008",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes

AU - Eisenhofer, Graeme

AU - Walther, McClellan M.

AU - Huynh, Thanh Truc

AU - Li, Sheng Ting

AU - Bornstein, Stefan R.

AU - Vortmeyer, Alexander

AU - Mannelli, Massimo

AU - Goldstein, David S.

AU - Linehan, W. Marston

AU - Lenders, Jacques W.M.

AU - Pacak, Karel

PY - 2001/1/1

Y1 - 2001/1/1

N2 - This study examined the mechanisms linking different biochemical and clinical phenotypes of pheochromocytoma in multiple endocrine neoplasia type 2 (MEN 2) and von Hippel-Lindau (VHL) syndrome to underlying differences in the expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, and of phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts norepinephrine to epinephrine. Signs and symptoms of pheochromocytoma, plasma catecholamines and metanephrines, and tumor cell neurochemistry and expression of TH and PNMT were examined in 19 MEN 2 patients and 30 VHL patients with adrenal pheochromocytomas. MEN 2 patients were more symptomatic and had a higher incidence of hypertension (mainly paroxysmal) and higher plasma concentrations of metanephrines, but paradoxically lower total plasma concentrations of catecholamines, than VHL patients. MEN 2 patients all had elevated plasma concentrations of the epinephrine metabolite, metanephrine, whereas VHL patients showed specific increases in the norepinephrine metabolite, normetanephrine. The above differences in clinical presentation were largely explained by lower total tissue contents of catecholamines and expression of TH and negligible stores of epinephrine and expression of PNMT in pheochromocytomas from VHL than from MEN 2 patients. Thus, mutation-dependent differences in the expression of genes controlling catecholamine synthesis represent molecular mechanisms linking the underlying mutation to differences in clinical presentation of pheochromocytoma in patients with MEN 2 and the VHL syndrome.

AB - This study examined the mechanisms linking different biochemical and clinical phenotypes of pheochromocytoma in multiple endocrine neoplasia type 2 (MEN 2) and von Hippel-Lindau (VHL) syndrome to underlying differences in the expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, and of phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts norepinephrine to epinephrine. Signs and symptoms of pheochromocytoma, plasma catecholamines and metanephrines, and tumor cell neurochemistry and expression of TH and PNMT were examined in 19 MEN 2 patients and 30 VHL patients with adrenal pheochromocytomas. MEN 2 patients were more symptomatic and had a higher incidence of hypertension (mainly paroxysmal) and higher plasma concentrations of metanephrines, but paradoxically lower total plasma concentrations of catecholamines, than VHL patients. MEN 2 patients all had elevated plasma concentrations of the epinephrine metabolite, metanephrine, whereas VHL patients showed specific increases in the norepinephrine metabolite, normetanephrine. The above differences in clinical presentation were largely explained by lower total tissue contents of catecholamines and expression of TH and negligible stores of epinephrine and expression of PNMT in pheochromocytomas from VHL than from MEN 2 patients. Thus, mutation-dependent differences in the expression of genes controlling catecholamine synthesis represent molecular mechanisms linking the underlying mutation to differences in clinical presentation of pheochromocytoma in patients with MEN 2 and the VHL syndrome.

UR - http://www.scopus.com/inward/record.url?scp=17744374251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744374251&partnerID=8YFLogxK

U2 - 10.1210/jcem.86.5.7496

DO - 10.1210/jcem.86.5.7496

M3 - Article

VL - 86

SP - 1999

EP - 2008

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -